SBRT should be offered to all patients with NSCLC regardless of comorbidities

Stereotactic body radiotherapy (SBRT) should be offered to all patients with peripheral stage 1 non-small cell lung cancer (NSCLC) regardless of their comorbidities, unless performance status and comorbidities prevent accurate SBRT planning and administration, according to a study published in the Journal of Thoracic Oncology.

Oncology Nurse Advisor